Investing in early detection

AmyGo Solutions is developing a blood test for transthyretin amyloidosis, a fatal, underdiagnosed disease that damages the heart and nerves.

 

Our work has been recognized through two NIH SBIR Phase I awards through the NIH and NSF, a 2026 Rising Star designation from BioNTX. Our science is grounded in peer-reviewed research published in Circulation and JACC: Basic to Translational Science.

 

We welcome the opportunity to connect with investors who want to learn more about our technology, our team, and our path forward.